Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed.

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Eli Lilly is on the verge of becoming the world's first pharmaceutical company to reach a market value of $1 trillion. This ...

Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.

The investment seeks to build upon Lilly's success from Mounjaro and Zepbound, which are riding a wave of popularity in so-called GLP-1 drugs. Lilly has 11 obesity drugs in its pipeline and wants ...

OpenAI closed its funding round at a $157 billion valuation. Tesla shares dropped after the EV maker missed estimates on ...

PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...

Cramer remains steadfast on Eli Lilly and Company (NYSE:LLY) as per Mad Money’s episode on September 30. Despite there being ...

The company is set to become the first $1tn drugmaker, but investors see warning signs it has reached ‘peak enthusiasm’ ...

However, GLP-1 users still need the gym. Studies suggest that the drugs cause significant muscle loss along with fat, leading to problems with balance and mobility as well as saggy skin sometimes ...